190 related articles for article (PubMed ID: 10330379)
1. Caffeine alters A2A adenosine receptors and their function in human platelets.
Varani K; Portaluppi F; Merighi S; Ongini E; Belardinelli L; Borea PA
Circulation; 1999 May; 99(19):2499-502. PubMed ID: 10330379
[TBL] [Abstract][Full Text] [Related]
2. Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and biochemical aspects.
Varani K; Portaluppi F; Gessi S; Merighi S; Ongini E; Belardinelli L; Borea PA
Circulation; 2000 Jul; 102(3):285-9. PubMed ID: 10899090
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of adenosine A2B receptors: studies in human mast cells co-expressing A2A and A2B adenosine receptor subtypes.
Feoktistov I; Biaggioni I
Biochem Pharmacol; 1998 Mar; 55(5):627-33. PubMed ID: 9515573
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of the new selective A2a adenosine receptor agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine.
Monopoli A; Conti A; Zocchi C; Casati C; Volpini R; Cristalli G; Ongini E
Arzneimittelforschung; 1994 Dec; 44(12):1296-304. PubMed ID: 7848347
[TBL] [Abstract][Full Text] [Related]
5. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
[TBL] [Abstract][Full Text] [Related]
6. Caffeine intake induces an alteration in human neutrophil A2A adenosine receptors.
Varani K; Portaluppi F; Gessi S; Merighi S; Vincenzi F; Cattabriga E; Dalpiaz A; Bortolotti F; Belardinelli L; Borea PA
Cell Mol Life Sci; 2005 Oct; 62(19-20):2350-8. PubMed ID: 16143823
[TBL] [Abstract][Full Text] [Related]
7. Signaling via A2A adenosine receptor in four PC12 cell clones.
Arslan G; Kull B; Fredholm BB
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):28-32. PubMed ID: 9933147
[TBL] [Abstract][Full Text] [Related]
8. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes.
Link AA; Kino T; Worth JA; McGuire JL; Crane ML; Chrousos GP; Wilder RL; Elenkov IJ
J Immunol; 2000 Jan; 164(1):436-42. PubMed ID: 10605040
[TBL] [Abstract][Full Text] [Related]
9. Characterization of adenosine receptors in the human bladder carcinoma T24 cell line.
Phelps PT; Anthes JC; Correll CC
Eur J Pharmacol; 2006 Apr; 536(1-2):28-37. PubMed ID: 16581066
[TBL] [Abstract][Full Text] [Related]
10. Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus.
Polak D; Talar M; Wolska N; Wojkowska DW; Karolczak K; Kramkowski K; Bonda TA; Watala C; Przygodzki T
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802928
[TBL] [Abstract][Full Text] [Related]
11. [3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes.
Varani K; Gessi S; Dionisotti S; Ongini E; Borea PA
Br J Pharmacol; 1998 Apr; 123(8):1723-31. PubMed ID: 9605581
[TBL] [Abstract][Full Text] [Related]
12. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.
Dionisotti S; Ferrara S; Molta C; Zocchi C; Ongini E
J Pharmacol Exp Ther; 1996 Sep; 278(3):1209-14. PubMed ID: 8819504
[TBL] [Abstract][Full Text] [Related]
13. Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets.
Cooper JA; Hill SJ; Alexander SP; Rubin PC; Horn EH
Br J Clin Pharmacol; 1995 Jul; 40(1):43-50. PubMed ID: 8527267
[TBL] [Abstract][Full Text] [Related]
14. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
Kull B; Arslan G; Nilsson C; Owman C; Lorenzen A; Schwabe U; Fredholm BB
Biochem Pharmacol; 1999 Jan; 57(1):65-75. PubMed ID: 9920286
[TBL] [Abstract][Full Text] [Related]
15. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
Zocchi C; Ongini E; Conti A; Monopoli A; Negretti A; Baraldi PG; Dionisotti S
J Pharmacol Exp Ther; 1996 Feb; 276(2):398-404. PubMed ID: 8632302
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A
Fuentes E; Fuentes M; Caballero J; Palomo I; Hinz S; El-Tayeb A; Müller CE
Platelets; 2018 May; 29(3):292-300. PubMed ID: 28504052
[TBL] [Abstract][Full Text] [Related]
17. Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H]SCH58261 to coronary artery membranes.
Belardinelli L; Shryock JC; Ruble J; Monopoli A; Dionisotti S; Ongini E; Dennis DM; Baker SP
Circ Res; 1996 Dec; 79(6):1153-60. PubMed ID: 8943953
[TBL] [Abstract][Full Text] [Related]
18. Evidence for co-expression and desensitization of A2a and A2b adenosine receptors in NG108-15 cells.
Mundell SJ; Kelly E
Biochem Pharmacol; 1998 Mar; 55(5):595-603. PubMed ID: 9515570
[TBL] [Abstract][Full Text] [Related]
19. 2-Substituted N-ethylcarboxamidoadenosine derivatives as high-affinity agonists at human A3 adenosine receptors.
Klotz KN; Camaioni E; Volpini R; Kachler S; Vittori S; Cristalli G
Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):103-8. PubMed ID: 10494877
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding.
Varani K; Gessi S; Dalpiaz A; Borea PA
Br J Pharmacol; 1996 Apr; 117(8):1693-701. PubMed ID: 8732278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
